Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
16.11.2022

SAN DIEGO, February 17, 2011 — Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C (HCV) null responder patient population. Safety, tolerability, and antiviral activity of the triple combination […]

Read more
Conatus pharmaceuticals completes $27.5 million private placement financing.
16.11.2022

SAN DIEGO, January 3, 2007 — Conatus Pharmaceuticals Inc. today announced the $5.5 million first closing of a $27.5 million Preferred Stock private placement financing led by Aberdare Ventures. In addition to Aberdare, investors include Advent Venture Partners, Bay City Capital, and Gilde Healthcare Partners. Conatus will use the proceeds to advance the clinical development […]

Read more
Conatus pharmaceuticals completes $20 million Series B private placement financing.
16.11.2022

SAN DIEGO, February 11, 2011 — Conatus Pharmaceuticals Inc. today announced the closing of a $20 million Series B Preferred Stock private placement financing. This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participation by existing investors; Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners, and […]

Read more